D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

Announce initial clinical data from Cohort 1 in the Phase 1/2 trial of PM359 for p47 phox CGD in 2025. The initial readout ...

President Donald Trump signed an executive order Monday updating guidance for researchers and government agencies with the ...

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to date Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) ...

Under the theme " Nurture the Present, Venture Forward ", the Food & Beverage lnnovation Forum 2025 (FBIF2025) and FBlF Food ...

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expect ...

Welcome to Definitive Healthcare's Q1 2025 earnings call. Later, we will conduct a question-and-answer session. I would now like to turn the call over to your host. You may begin. Good afternoon.

Unity Biotechnology, a Bay Area company that once ... the company by May 15 and that it’s estimating severance and other related costs of $3.7 million. That’s a solid chunk of the $16.9 ...

Microbiologist and entrepreneur Jesse Labbé excels at cultivating discovery and innovation. As the new director of the ...

PI, a global leader in precision motion control and nanopositioning, announces fast delivery of its nanometer-precise, high-speed V-308 vertical nanopositioning stage. The system offers 7 mm of ...

WASHINGTON (AP) — Dr. Vinay Prasad, a prominent critic of the pharmaceutical industry and the Food and Drug Administration, ...

Tensions rise in Korea's pharma sector as Trump plans drug tariffs. Companies like Samsung Biologics monitor the situation ...